Farallon Capital Management LLC Reduces Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Farallon Capital Management LLC lessened its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 99.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the company’s stock after selling 1,666,000 shares during the period. Farallon Capital Management LLC’s holdings in Hims & Hers Health were worth $202,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Arizona State Retirement System boosted its holdings in shares of Hims & Hers Health by 3.0% in the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock valued at $815,000 after purchasing an additional 1,173 shares during the period. Belpointe Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after purchasing an additional 1,205 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 6.6% in the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after purchasing an additional 1,212 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the period. Finally, Swiss National Bank boosted its holdings in shares of Hims & Hers Health by 0.7% in the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after purchasing an additional 2,000 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In related news, insider Michael Chi sold 9,313 shares of the company’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $22.00, for a total value of $204,886.00. Following the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total value of $3,919,426.00. Following the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $695,166.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Michael Chi sold 9,313 shares of the company’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $22.00, for a total transaction of $204,886.00. Following the completion of the sale, the insider now directly owns 185,326 shares in the company, valued at $4,077,172. The disclosure for this sale can be found here. Insiders have sold a total of 731,473 shares of company stock valued at $12,671,277 in the last ninety days. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Trading Up 0.7 %

Shares of HIMS stock opened at $16.41 on Tuesday. The business’s fifty day simple moving average is $17.35 and its 200-day simple moving average is $17.09. Hims & Hers Health, Inc. has a 12-month low of $5.65 and a 12-month high of $25.74. The company has a market cap of $3.52 billion, a PE ratio of -1,641.00 and a beta of 1.05.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The firm had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same period in the prior year, the firm earned ($0.03) EPS. The firm’s revenue was up 51.8% on a year-over-year basis. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. Piper Sandler reissued a “neutral” rating and issued a $18.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. TD Cowen boosted their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Finally, Needham & Company LLC started coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.